Notably, nanovaccines engulfed by ID8 cells can reduce CD47 expression without compromising cell proliferation, thereby enhancing macrophage phagocytosis by attenuating the CD47‐SIRPα inhibitory signaling.[26] In the ID8 tumor‐bearing mouse model, our findings indicate that the nanovaccine can reverse the paclitaxel‐induced increase in M2‐like TAMs, achieving a synergistic anti‐ovarian cancer effect when combined with chemotherapy. The gene discussed is CD47; the disease is ovarian carcinoma.